These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 812998)

  • 1. Mucoid strains of Pseudomonas aeruginosa: the influence of culture medium on the stability of mucus production.
    Govan JR
    J Med Microbiol; 1975 Nov; 8(4):513-22. PubMed ID: 812998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of nutrient media on the chemical composition of the exopolysaccharide from mucoid and non-mucoid Pseudomonas aeruginosa.
    Marty N; Dournes JL; Chabanon G; Montrozier H
    FEMS Microbiol Lett; 1992 Nov; 77(1-3):35-44. PubMed ID: 1459419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Pseudomonas aeruginosa from cystic fibrosis by selective media.
    Fonseca K; MacDougall J; Pitt TL
    J Clin Pathol; 1986 Feb; 39(2):220-2. PubMed ID: 3081597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of nutrient media on the characteristics of the exopolysaccharide produced by three mucoid Pseudomonas aeruginosa strains.
    Buckmire FL
    Microbios; 1984; 41(163):49-63. PubMed ID: 6441885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An aerobiological model of aerosol survival of different strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis.
    Clifton IJ; Fletcher LA; Beggs CB; Denton M; Conway SP; Peckham DG
    J Cyst Fibros; 2010 Jan; 9(1):64-8. PubMed ID: 19944655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a new agar medium containing cetrimide, kanamycin and nalidixic acid for isolation and enhancement of pigment production of Pseudomonas aeruginosa in clinical samples.
    Kodaka H; Iwata M; Yumoto S; Kashitani F
    J Basic Microbiol; 2003; 43(5):407-13. PubMed ID: 12964184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of mucoid strains of Pseudomonas aeruginosa in bacteriological specimens from patients with cystic fibrosis and patients with other diseases.
    Hoiby N
    Acta Pathol Microbiol Scand Suppl; 1975 Dec; 83(6):549-52. PubMed ID: 812334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotyping of Pseudomonas aeruginosa isolates from patients with cystic fibrosis of the pancreas.
    Zierdt CH; Williams RL
    J Clin Microbiol; 1975 Jun; 1(6):521-6. PubMed ID: 809484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxygen, cyanide and energy generation in the cystic fibrosis pathogen Pseudomonas aeruginosa.
    Williams HD; Zlosnik JE; Ryall B
    Adv Microb Physiol; 2007; 52():1-71. PubMed ID: 17027370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of nonmucoid derivatives of mucoid Pseudomonas aeruginosa is strongly influenced by the level of iron in the culture medium.
    Boyce JR; Miller RV
    Infect Immun; 1982 Aug; 37(2):695-701. PubMed ID: 6811438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of characterised Pseudomonas aeruginosa exopolysaccharides on adherence to human tracheal cells.
    Marty N; Pasquier C; Dournes JL; Chemin K; Chavagnat F; Guinand M; Chabanon G; Pipy B; Montrozier H
    J Med Microbiol; 1998 Feb; 47(2):129-34. PubMed ID: 9879955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucoid Pseudomonas in cystic fibrosis.
    Pritt B; O'Brien L; Winn W
    Am J Clin Pathol; 2007 Jul; 128(1):32-4. PubMed ID: 17580270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS
    APMIS Suppl; 1992; 28():1-79. PubMed ID: 1449848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic differences among clinically isolated mucoid Pseudomonas aeruginosa strains.
    Pugashetti BK; Metzger HM; Vadas L; Feingold DS
    J Clin Microbiol; 1982 Oct; 16(4):686-91. PubMed ID: 6818245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of surfactants on the dissolution profiles of poorly water-soluble acidic drugs.
    Park SH; Choi HK
    Int J Pharm; 2006 Sep; 321(1-2):35-41. PubMed ID: 16797892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms.
    Alkawash MA; Soothill JS; Schiller NL
    APMIS; 2006 Feb; 114(2):131-8. PubMed ID: 16519750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients.
    Lee B; Schjerling CK; Kirkby N; Hoffmann N; Borup R; Molin S; Høiby N; Ciofu O
    APMIS; 2011 Apr; 119(4-5):263-74. PubMed ID: 21492226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucoid Escherichia coli in cystic fibrosis.
    Macone AB; Pier GB; Pennington JE; Matthews WJ; Goldmann DA
    N Engl J Med; 1981 Jun; 304(24):1445-9. PubMed ID: 6785645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological markers for Pseudomonas aeruginosa. 6. Relationship between concomitant non-mucoid and mucoid strains from the respiratory tract in cystic fibrosis.
    Bergan T; Hoiby N
    Acta Pathol Microbiol Scand Suppl; 1975 Dec; 83(6):553-60. PubMed ID: 812335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.